No description available.

No description available.

No description available.

No description available.

No description available.

No description available.

Copies of author's previously published works inserted. / Bibliography: leaves 321-370. / xv, 370, [21] leaves : ill. (chiefly col.) ; 30 cm. / Title page, contents and abstract only. The complete thesis in print form is available from the University Library. / The aim of the project presented in this thesis is to isolate microsatellite markers and to construct a high resolution genetic map of the human X chromosome using these and pre-existing microsatellite markers. AC dinucleotide repeat markers are isolated from a bacteriophage library for application to the genetic localisations of X-linked disease genes, particularly those responsible for non-specific mental retardation (MRX). The genetic map is used to refine the location of the disease gene segregating in five families affected with X-linked mental retardation. / Thesis (Ph.D.)--University of Adelaide, Dept. of Genetics, 1997

No description available.

Turner Syndrome (TS) is a chromosomal disorder from conception characterized by the partial or complete absence of the second X chromosome in females. Chromosomal abnormalities, both numerical and structural, contribute to a significantly higher prevalence of fractures (30.5-32.2%) compared to non-TS postmenopausal women (14.9%). This highlights the intrinsic bone abnormalities associated with TS and increased fracture risk. Peripheral quantitative computed tomography (pQCT) is commonly used to assess bone mineral density (BMD). However, its accuracy in individuals with TS is limited due to the partial volume effect, highlighting the need for further clinical research to understand bone density changes compared to healthy controls. Osteoporosis is a significant comorbidity in TS, characterized by reduced bone quality and altered microstructure. Factors directly contributing to osteoporosis in TS include X chromosome abnormalities, hormonal imbalances, metabolic syndrome, and autoimmune disease. Current management strategies involve estrogen and growth hormone replacement, along with progastrin and bisphosphonates. Therapies targeting the inhibitors of the Wnt/β-catenin pathway could improve BMD and bone quality and reduce fracture risk. However, more clinical research is needed to understand the bone density compositional changes that occur to optimize therapeutic approaches for individuals with TS.